14,765 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Purchased by Headlands Technologies LLC

Headlands Technologies LLC bought a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 14,765 shares of the company’s stock, valued at approximately $228,000.

Other hedge funds have also recently modified their holdings of the company. Belpointe Asset Management LLC lifted its holdings in shares of Hims & Hers Health by 10.0% during the 4th quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock valued at $118,000 after purchasing an additional 1,205 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Hims & Hers Health by 5.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,335 shares of the company’s stock valued at $261,000 after buying an additional 1,561 shares in the last quarter. Swiss National Bank lifted its stake in Hims & Hers Health by 0.7% in the 1st quarter. Swiss National Bank now owns 281,500 shares of the company’s stock valued at $4,355,000 after buying an additional 2,000 shares in the last quarter. Principal Financial Group Inc. lifted its stake in Hims & Hers Health by 17.9% in the 1st quarter. Principal Financial Group Inc. now owns 16,655 shares of the company’s stock valued at $258,000 after buying an additional 2,525 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its stake in Hims & Hers Health by 23.0% in the 4th quarter. Victory Capital Management Inc. now owns 18,348 shares of the company’s stock valued at $163,000 after buying an additional 3,429 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Citigroup lowered shares of Hims & Hers Health from a “buy” rating to a “neutral” rating and raised their price target for the company from $16.00 to $20.00 in a research note on Wednesday, May 22nd. Seaport Res Ptn reaffirmed a “buy” rating on shares of Hims & Hers Health in a research note on Friday, April 26th. Canaccord Genuity Group raised their target price on shares of Hims & Hers Health from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, May 22nd. Piper Sandler raised their target price on shares of Hims & Hers Health from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Thursday, July 11th. Finally, TD Cowen raised their target price on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Seven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $18.36.

Insider Transactions at Hims & Hers Health

In other news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $12.54, for a total value of $2,368,655.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $12.54, for a total transaction of $2,368,655.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Christiane Pendarvis sold 4,000 shares of the business’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $12.33, for a total transaction of $49,320.00. Following the transaction, the director now directly owns 11,210 shares of the company’s stock, valued at $138,219.30. The disclosure for this sale can be found here. Insiders sold 971,868 shares of company stock valued at $18,372,614 over the last 90 days. Corporate insiders own 17.71% of the company’s stock.

Hims & Hers Health Stock Performance

HIMS traded up $0.22 on Tuesday, hitting $23.06. 5,621,329 shares of the company were exchanged, compared to its average volume of 7,387,873. The business’s fifty day moving average is $19.53 and its 200 day moving average is $14.51. Hims & Hers Health, Inc. has a fifty-two week low of $5.65 and a fifty-two week high of $25.74. The firm has a market capitalization of $4.95 billion, a P/E ratio of -2,344.00 and a beta of 1.08.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, May 6th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.03. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. The business had revenue of $278.20 million for the quarter, compared to the consensus estimate of $270.37 million. During the same quarter in the prior year, the firm posted ($0.05) earnings per share. The company’s quarterly revenue was up 45.8% compared to the same quarter last year. Analysts forecast that Hims & Hers Health, Inc. will post 0.2 EPS for the current fiscal year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.